Giv­ing it a GO: Gi­ant Roche se­lects a tiny play­er at Lab­Cen­tral for its next can­cer R&D part­ner

7 years ago
R&D
Pharma

Buck­ing the trend, Antares gains FDA OK for testos­terone in­jec­tion on sec­ond try

7 years ago
Pharma

J&J shrugs off deals with Aduro that were worth up to $1.2B. Set­back forces shift to No­var­tis al­liance now

7 years ago
R&D

Avro­bio shares blast­ed af­ter tri­al up­date sours out­look on gene ther­a­py for Fab­ry dis­ease

7 years ago
Cell/Gene Tx

Mo­men­ta whacks top ex­ecs, 110 jobs in re­struc­tur­ing; Genen­tech gains $62M in R&D back­ing from BAR­DA

7 years ago
News Briefing

Nas­daq wraps up Q3 with IPO pitch­es from Gami­da Cell, NGM, Arog to­talling $219M

7 years ago
Financing

In­smed fol­lows a new path­way at the FDA for an­tibac­te­ri­als, win­ning quick OK for Arikayce

7 years ago
Pharma

Mer­ck’s can­cer R&D jug­ger­naut ties up to lit­tle Drag­on­fly’s nat­ur­al born killer plat­form — with bil­lions on the ...

7 years ago
R&D
Pharma

Three years af­ter sell­ing Ac­er­ta to As­traZeneca in $7B deal, Dave John­son is back at the helm of a biotech start­up

7 years ago
Financing
Startups

Can­cer R&D stars Jim Al­li­son, Tasuku Hon­jo award­ed No­bel prize for im­munother­a­py dis­cov­er­ies

7 years ago
People

Ian Read taps his care­ful­ly groomed suc­ces­sor Al­bert Bourla as the next Pfiz­er CEO. What's his fu­ture look like?

7 years ago
People
Peer Review

Ex-Ker­ris­dale an­a­lyst sets out to tor­pe­do Nek­tar with a blunt short at­tack on star drug NK­TR-214: 'It doesn’t work'

7 years ago
Pharma

A speedy FDA of­fers light­ning re­view and quick OK for the lat­est PD-1 from Re­gen­eron and Sanofi

7 years ago
Pharma

Fred Aslan re­turns to biotech as pres­i­dent of Vi­vid­ion; Zai Lab scoops Por­to­la's Tao Fu to spear­head US op­er­a­tions

7 years ago
Peer Review

UK biotech sees boost in biotech fundrais­ing so far this year; Chemo­Cen­tryx kills plans for stock of­fer

7 years ago
News Briefing

Loy­ola is work­ing on a new and im­proved CAR-T prod­uct, look­ing to over­come high-fre­quen­cy side ef­fects

7 years ago
Startups
R&D

On the heels of a glob­al R&D re­or­ga­ni­za­tion, No­vo Nordisk out­lines 250 US job cuts

7 years ago
R&D

Grit­stone’s top-of-the-range IPO brings week’s biotech Nas­daq tal­ly to $520M

7 years ago
Financing

Pfiz­er nabs fast OK for a new front­line lung can­cer drug as phar­ma gi­ant shows off its new R&D strat­e­gy

7 years ago
Pharma

Gen­script re­bounds on HKEX with staunch de­fense of Leg­end Biotech's CAR-T da­ta in­tegri­ty

7 years ago
China

Roche scoops up a Treg play­er for the I/O team, pluck­ing 1 drug and spin­ning off a 2nd in­to a new biotech

7 years ago
Deals

Fast-grow­ing KSQ and David Meek­er fu­el up with a hefty $80M round on the way to first hu­man stud­ies

7 years ago
Financing

Watch out Am­gen and Te­va, Eli Lil­ly got its green light for a ri­val CGRP mi­graine drug — and they’re com­ing af­ter ...

7 years ago
Pharma

New York can­cer cen­ter launch­es 'his­toric' JV to bring Cuban-de­vel­oped can­cer drugs to US

7 years ago
Financing
First page Previous page 992993994995996997998 Next page Last page
A service from the Financial Times